




New peptide-based drug with anti-angiogenic properties

Technology

TAX2 is a new peptide-based drug with anti-angiogenic properties, designed through innovative interdisciplinary approaches (bioinformatics, molecular modeling, biochemical and molecular biology).

The peptide has specific antagonistic properties of the interaction thrombospondin-1 (TSP-1):CD47, which has many pharmacological and therapeutic consequences.



Benefits

- Anti-angiogenic activity
- A strong anti-tumor and anti-metastatic potential
- Side-effects reduction:
 - More continuous and moderate anti-angiogenic response: reduction of thrombosis, stroke and embolism
 - No vascular alteration in other organs (brain, lungs) whereas existing drugs cause significant damage
- TAX2 is active in various tissues (pancreas, melanoma, ovarian, lung)
- This receptor is a new target leading to a therapeutic alternative

Applications

- Development of anti-angiogenic and anti-metastatic strategies
- Decrease the resistance of cancer cells to chemotherapeutic or combinatorial treatment

Keywords

- new peptide-based drug
- anti-angiogenic properties
- interaction TSP-1:CD47

Intellectual Property

French priority patent filed on July 8, 2011 and PCT/FR2012/051593 on July 6, 2012

National phases validated for USA, Canada, Europe and Japan

Development Status

In vitro, ex vivo and in vivo validations:

- lung metastasis model
- melanoma model (allograft)
- pancreatic carcinoma model (xenografts)
- ovarian carcinoma model (xenografts)

ADMET validation (performed by a CRO):

- bioavailability, distribution and half-life measured no toxicity even at high dose

Partnership

Partnerships to achieve the development in the best therapeutic application **and/or** out-licensing

contact

Anthony DACCACHE, Ph.D.

Business Developer

+33 6 13 84 39 39

anthony.daccache@sattnord.fr

find other technologies on www.sattnord.fr



SATT Nord

25, avenue Charles St Venant – 59800 LILLE – France

+33 3 28 36 04 68 – tech@sattnord.fr